Pharmacological treatment is widely used to manage the symptoms of venous disease in some countries in Europe, and yet rarely used in others. In France and Italy 'phlebotonic' drugs are in common usage, to the extent that half the heaJthcare expenditure on venous disease is spent on pharmacological treatments. In the United Kingdom and other northern European countries very few of these are prescribed. In the UK only one drug (Paroven/ Venoruton, Zyma Healthcare) has a product licence and expenditure on this amounts to less than 1% of the total healthcare costs for the management of venous disease.
So, are doctors in countries where phlebotonic drugs are not used denying their patients a useful alternative to surgical treatment? Or are physicians where these drugs are widely prescribed guilty of needless extravagance? There are many studies which show that these are effective in managing the symptoms of venous disease when compared to controls. The paper by Pillion et aI. in this issue demonstrates efficacy of a flavonoid fraction in the mitigation of venous disease symptoms, and the paper by Vin et al. shows the efficacy of Troxerutin in the management of venous disease. These papers concentrate on the influence of the drug on the symptomatic response, but also include objective measures of physiological or haematological response. The studies were conducted in a double-blind study design and clearly show a therapeutic response. Ernst et al. have investigated the placebo effect of pharmacological treatments. They have shown that 'pills for veins' have a powerful placebo effect, which may be exceeded by the placebo effect ofan ointment to rub on the affected limb.
Some studies have shown more rapid ulcer healing in response to pharmacological treatment. but one large study failed to show any efficacy in preventing ulcer recurrence when using hydroxy nutosides in patients with healed ulcers. The most important issue to resolve is whether drug treatment has a large enough effect to avert the need for surgical intervention. I am not aware of any study in which this question has been properly addressed. The future of pharmacological treatments for venous disease may depend upon properly conducted studies which answer this point.
The presently used phlebotonic treatments do not make venous valvular incompetence disappear. Drugs which restore the competence of varicose veins are unlikely to be developed in the next decade, although drugs which heal and maintain the healing of venous ulcers might be. Our rapidly expanding understanding of the biology of blood vessels may lead to the possibility of developing drugs which might be effective in such areas. A full knowledge of the mechanisms leading to venous disease is highly desirable so that appropriate mechanisms of action for the new generation of drugs may be designed. Considerable research effort is currently expended to resolve the complex series of events which occur during critical ischaemia. The mechanisms responsible are almost certainly fundamental to mammalian microvascular metabolism and therefore drugs which manipulate them may be effective in many inflammatory disorders. including those which culminate in venous ulceration.
The current generation of drugs used to treat venous disease have a clearly demonstrable effect in controlled studies. Perhaps the magnitude of their effect is, as yet, insufficient to convince the physicians of all countries that they should be widely prescribed.
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